Lineage's OpRegen Shows +9 Letter BCVA Gains At 3 Years With Extensive Cell Coverage In Phase 1/2a Trial For Geographic Atrophy
Benzinga Newsdesk 1 year ago
News
Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion siteEvidence of retinal structural improvement persisted out to 3 yearsAnatomical and
- Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion site
- Evidence of retinal structural improvement persisted out to 3 years
- Anatomical and functional improvements occur following a single administration of OpRegen cell therapy